TY - JOUR
T1 - 新型冠状病毒肺炎防控形势下急性心肌梗死诊治流程和路径的中国专家共识(第1版)
AU - Jun, Bu
AU - Mao, Chen
AU - Xiaoshu, Cheng
AU - Yifei, Dong
AU - Weiyi, Fang
AU - Junbo, Ge
AU - Yanjun, Gong
AU - Ben, He
AU - Lan, Huang
AU - Yong, Huo
AU - Shaobin, Jia
AU - Jun, Jiang
AU - Yue, Li
AU - Zhao, Li
AU - Chun, Liang
AU - Xuebo, Liu
AU - Zhenyu, Liu
AU - Xiang, Ma
AU - Yitong, Ma
AU - Juying, Qian
AU - Chengxing, Shen
AU - Difei, Shen
AU - Li, Shen
AU - Ruizheng, Shi
AU - Xi, Su
AU - Yingxian, Sun
AU - Yida, Tang
AU - Jianan, Wang
AU - Yue, Wu
AU - Dingcheng, Xiang
AU - Tongda, Xu
AU - Yawei, Xu
AU - Yuejin, Yang
AU - Hesong, Zeng
AU - Cheng, Zhang
AU - Guogang, Zhang
AU - Ruiyan, Zhang
AU - Shuning, Zhang
AU - Yun, Zhang
AU - Zheng, Zhang
AU - Bo, Zheng
AU - Ning, Zhou
N1 - Publisher Copyright:
© 2020 Editorial Department of Journal of Southern Medical University. All rights reserved.
PY - 2020
Y1 - 2020
N2 - The SARS-CoV-2 epidemic starting in Wuhan in December, 2019 has spread rapidly throughout the nation. The control measures to contain the epidemic also produced influences on the transport and treatment process of patients with acute myocardial infarction (AMI), and adjustments in the management of the patients need to be made at this particular time. AMI is characterized by an acute onset with potentially fatal consequence, a short optimal treatment window, and frequent complications including respiratory infections and respiratory and circulatory failure, for which active on-site treatment is essential. To standardize the management and facilitate the diagnosis and treatment, we formulated the guidelines for the procedures and strategies for the diagnosis and treatment of AMI, which highlight 5 Key Principles, namely Nearby treatment, Safety protection, Priority of thrombolysis, Transport to designated hospitals, and Remote consultation. For AMI patients, different treatment strategies are selected based on the screening results of SARS-CoV-2, the time window of STEMI onset, and the vital signs of the patients. During this special period, the cardiologists, including the interventional physicians, should be fully aware of the indications and contraindications of thrombolysis. In the transport and treatment of AMI patients, the physicians should strictly observe the indications for patient transport with appropriate protective measurements of the medical staff.
AB - The SARS-CoV-2 epidemic starting in Wuhan in December, 2019 has spread rapidly throughout the nation. The control measures to contain the epidemic also produced influences on the transport and treatment process of patients with acute myocardial infarction (AMI), and adjustments in the management of the patients need to be made at this particular time. AMI is characterized by an acute onset with potentially fatal consequence, a short optimal treatment window, and frequent complications including respiratory infections and respiratory and circulatory failure, for which active on-site treatment is essential. To standardize the management and facilitate the diagnosis and treatment, we formulated the guidelines for the procedures and strategies for the diagnosis and treatment of AMI, which highlight 5 Key Principles, namely Nearby treatment, Safety protection, Priority of thrombolysis, Transport to designated hospitals, and Remote consultation. For AMI patients, different treatment strategies are selected based on the screening results of SARS-CoV-2, the time window of STEMI onset, and the vital signs of the patients. During this special period, the cardiologists, including the interventional physicians, should be fully aware of the indications and contraindications of thrombolysis. In the transport and treatment of AMI patients, the physicians should strictly observe the indications for patient transport with appropriate protective measurements of the medical staff.
KW - myocardial infarction
KW - novel coronavirus pneumonia
KW - protection
KW - thrombolysis
KW - transshipment
UR - https://www.scopus.com/pages/publications/85084328032
U2 - 10.12122/j.issn.1673-4254.2020.02.01
DO - 10.12122/j.issn.1673-4254.2020.02.01
M3 - 文章
C2 - 32376532
AN - SCOPUS:85084328032
SN - 1673-4254
VL - 40
SP - 147
EP - 151
JO - Nan Fang Yi Ke Da Xue Xue Bao / Journal of Southern Medical University
JF - Nan Fang Yi Ke Da Xue Xue Bao / Journal of Southern Medical University
IS - 2
ER -